AC Immune SA (NASDAQ:ACIU) shares traded up 6.5% during mid-day trading on Monday . The stock traded as high as $5.83 and last traded at $5.73, 15,415 shares traded hands during trading. A decline of 85% from the average session volume of 99,847 shares. The stock had previously closed at $5.38.

Several analysts have recently issued reports on the stock. BidaskClub raised shares of AC Immune from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. HC Wainwright set a $8.00 price target on shares of AC Immune and gave the stock a “buy” rating in a research report on Friday, July 12th. Finally, ValuEngine raised shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Wednesday, June 12th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $11.94.

The company’s 50-day moving average price is $5.47 and its 200-day moving average price is $4.98. The firm has a market cap of $374.28 million, a price-to-earnings ratio of -6.99 and a beta of 0.02. The company has a quick ratio of 5.06, a current ratio of 21.90 and a debt-to-equity ratio of 0.01.

A number of large investors have recently modified their holdings of ACIU. Cubist Systematic Strategies LLC acquired a new stake in AC Immune in the second quarter valued at approximately $58,000. Marshall Wace North America L.P. raised its holdings in AC Immune by 625.8% in the first quarter. Marshall Wace North America L.P. now owns 15,836 shares of the company’s stock valued at $80,000 after acquiring an additional 13,654 shares in the last quarter. Appleton Partners Inc. MA acquired a new stake in AC Immune in the second quarter valued at approximately $85,000. JPMorgan Chase & Co. raised its holdings in AC Immune by 20.7% in the second quarter. JPMorgan Chase & Co. now owns 18,162 shares of the company’s stock valued at $99,000 after acquiring an additional 3,113 shares in the last quarter. Finally, Spark Investment Management LLC acquired a new stake in AC Immune in the first quarter valued at approximately $115,000. 25.54% of the stock is currently owned by hedge funds and other institutional investors.

About AC Immune (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Recommended Story: What is the 52-week high/low?

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.